Ultragenyx Pharmaceutical: Of Form 8k, Ultragenyx Pharmaceutical Inc. (the Company ) Is Filing This Amendment No. 1 To Its Current Report On Form 8k Originally Filed On June 27, 2022 (the Initial 8k ) That Reported The Voting Results From Its Annual Meeting Of Stockholders Held On June 24, 2022 (the Annual Meeting ) Solely For The Purpose Of Updating The Disclosure Under Item 5.07 Submission Of Matters To A Vote Of Security Holders To Provide Information Regarding The Determination Of The Board Of Directors Of The Company As To Frequency Of Future Shareholder Advisory Votes On The Compensation Of The Company S Named Executive Officers. Except For The Foregoing, This Amendment Does Not Modify Or Update Any Other Disclosure Contained In The Initial 8k

Show full article

This functionality is available for registred users only

• Full name
  Ultragenyx Pharmaceutical Inc.
• Registration country
  USA
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***